DOP2013000043A - Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos - Google Patents

Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos

Info

Publication number
DOP2013000043A
DOP2013000043A DO2013000043A DO2013000043A DOP2013000043A DO P2013000043 A DOP2013000043 A DO P2013000043A DO 2013000043 A DO2013000043 A DO 2013000043A DO 2013000043 A DO2013000043 A DO 2013000043A DO P2013000043 A DOP2013000043 A DO P2013000043A
Authority
DO
Dominican Republic
Prior art keywords
cells
compositions
methods
lymphatic
progenitating
Prior art date
Application number
DO2013000043A
Other languages
English (en)
Inventor
Theresa Deisher
Original Assignee
Theresa Deisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theresa Deisher filed Critical Theresa Deisher
Publication of DOP2013000043A publication Critical patent/DOP2013000043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para inhibir la unión de células madre a órganos y tejidos, que incluye el bloqueo de la unión de células madre a centros germinales presentes en el tejido linfático. Se describen composiciones y métodos para regenerar los centros germinales en el tejido linfático. En las composiciones se incluyen adyuvantes, agonistas del receptor de CD40, CD28 y IL-21 y antagonista de CD20. .
DO2013000043A 2010-08-18 2013-02-14 Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos DOP2013000043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37494310P 2010-08-18 2010-08-18
US201161441485P 2011-02-10 2011-02-10
US201161449372P 2011-03-04 2011-03-04

Publications (1)

Publication Number Publication Date
DOP2013000043A true DOP2013000043A (es) 2013-09-30

Family

ID=45594254

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000043A DOP2013000043A (es) 2010-08-18 2013-02-14 Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos

Country Status (20)

Country Link
US (2) US20120045435A1 (es)
EP (2) EP3530274A1 (es)
JP (3) JP6096116B2 (es)
KR (3) KR101833204B1 (es)
CN (1) CN103167870B (es)
AU (1) AU2011291651B2 (es)
BR (1) BR112013003169B1 (es)
CA (1) CA2844109C (es)
CR (1) CR20130117A (es)
DO (1) DOP2013000043A (es)
ES (1) ES2738115T3 (es)
IL (1) IL224727B (es)
MX (1) MX368272B (es)
MY (1) MY179491A (es)
NZ (1) NZ607906A (es)
PH (1) PH12013500271A1 (es)
RU (1) RU2645069C2 (es)
SG (2) SG187840A1 (es)
WO (1) WO2012024519A2 (es)
ZA (2) ZA201301800B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
WO2016022656A1 (en) * 2014-08-05 2016-02-11 Wayne State University Compositions and methods for treatment of sickle cell disease
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
CN107034272B (zh) * 2016-12-14 2020-09-29 河北医科大学第四医院（河北省肿瘤医院） Cxcl2在制备诊断或治疗肺腺癌工具中的应用
CN110475571B (zh) * 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
AU2018374283B2 (en) * 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
RU2707281C1 (ru) * 2018-09-17 2019-11-26 Гордейчук Владимир Евгеньевич Способ иммунотерапии раковых заболеваний
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
BR112021009365A2 (pt) 2018-11-14 2021-08-10 Avm Biotechnology, Llc formulação de glicocorticoide estável
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
WO2021211450A1 (en) * 2020-04-13 2021-10-21 Fred Hutchinson Cancer Research Center Conditioning regimens for in vivo gene therapy
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
WO2021247000A1 (en) 2020-06-01 2021-12-09 Avm Biotechnology, Llc Methods of treatment using icam-modulating agents
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用
CN121431843B (zh) * 2025-12-31 2026-03-27 苏州市立医院 高性能中性粒细胞筛选方法和系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
GB9323199D0 (en) * 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
EP1395274A2 (en) * 2001-05-22 2004-03-10 Duke University Compositions and methods for inhibiting metastasis
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
DK1505973T3 (da) * 2002-05-17 2010-05-31 Celgene Corp Kombinationer til behandling af multipelt myelom
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
CA2589063C (en) * 2004-12-23 2016-08-09 DePuy Synthes Products, Inc. Treatment of parkinson's disease and related disorders using postpartum derived cells
US20080138415A1 (en) * 2006-09-26 2008-06-12 Mehboob Hussain Composition and method for producing composition for constructing tissue, and tissue construct
HUE036745T2 (hu) 2006-11-03 2018-07-30 Multiple Sclerosis Res Center Of New York Csontvelõ eredetû mesenchimális õssejtek, mint a neurális progenitor sejtek forrásai
WO2008094689A2 (en) * 2007-02-01 2008-08-07 Nephrogen, Llc Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
US20100135993A1 (en) * 2007-03-14 2010-06-03 The University Of Tokyo Method of treating malignant mesothelioma
JP4743215B2 (ja) 2008-02-07 2011-08-10 株式会社ジェイ・エム・エス 血液透析装置
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2010006261A1 (en) 2008-07-10 2010-01-14 Hong John J Methods for inducing stem cell migration and specialization with ec-18

Also Published As

Publication number Publication date
JP2014501694A (ja) 2014-01-23
AU2011291651A1 (en) 2013-03-21
WO2012024519A4 (en) 2012-06-28
US9962408B2 (en) 2018-05-08
JP6096116B2 (ja) 2017-03-15
MY179491A (en) 2020-11-08
PH12013500271A1 (en) 2024-02-12
CN103167870B (zh) 2018-11-16
MX2013001835A (es) 2013-02-26
ZA201402419B (en) 2015-12-23
CA2844109A1 (en) 2012-02-23
JP2019059744A (ja) 2019-04-18
RU2645069C2 (ru) 2018-02-15
EP2605765B1 (en) 2019-05-08
KR102173938B1 (ko) 2020-11-04
CR20130117A (es) 2013-05-31
US20170128493A1 (en) 2017-05-11
JP2017081948A (ja) 2017-05-18
ES2738115T3 (es) 2020-01-20
CA2844109C (en) 2018-11-06
AU2011291651B2 (en) 2016-01-14
KR20190017065A (ko) 2019-02-19
JP6437988B2 (ja) 2018-12-12
KR20140027901A (ko) 2014-03-07
WO2012024519A2 (en) 2012-02-23
CN103167870A (zh) 2013-06-19
BR112013003169A2 (pt) 2016-06-28
EP2605765A2 (en) 2013-06-26
EP3530274A1 (en) 2019-08-28
JP6716668B2 (ja) 2020-07-01
WO2012024519A3 (en) 2012-04-19
BR112013003169B1 (pt) 2022-05-24
KR101833204B1 (ko) 2018-03-02
US20120045435A1 (en) 2012-02-23
NZ607906A (en) 2015-11-27
SG10201600621VA (en) 2016-02-26
SG187840A1 (en) 2013-03-28
ZA201301800B (en) 2014-07-30
MX368272B (es) 2019-09-26
KR20180023040A (ko) 2018-03-06
IL224727B (en) 2018-02-28
RU2013110492A (ru) 2014-09-27

Similar Documents

Publication Publication Date Title
PH12013500271A1 (en) Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
MX2015004771A (es) Metodos para tratar cancer.
ECSP14004976A (es) Anticuerpos anti-il-36r
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2019011890A (es) Liberacion controlada de inmunosupresores a partir de nanoportadores sinteticos.
GT201400133A (es) Inhibidores de bromodominios
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
ECSP14013215A (es) Compuestos novedosos
BR112013022042A2 (pt) tecido não tecido contendo material de prótese óssea
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
CR20150171A (es) Benzamidas
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
ECSP14013158A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
MX2017009824A (es) Triazoles sustituidos y metodos relacionados a estos.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
UY34043A (es) Isoxazolinas como agentes terapéuticos
DOP2014000283A (es) Derivados de pirimidona como agentes antimalaricos